Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Yaz Approved for Dysmenorrhea: Bayer
August 9, 2010
- FPMAJ to Reduce CO2 Emissions by 23% in FY2020 vs FY2005
August 9, 2010
- Viviant Approved for Osteoporosis: Pfizer
August 9, 2010
- Nichi-Iko Ties Up with DKSH for Southeast Asian Market
August 9, 2010
- Forteo Approved for Osteoporosis: Eli Lilly
August 9, 2010
- AnGes MG Ties Up with EPS in China
August 9, 2010
- Volibris Approved for PAH: GSK
August 9, 2010
- Merck Ties Up with Sinopharm for Vaccine Business in China
August 9, 2010
- Onoact Approved for Improvement of Imaging Performance in CT-Based CAG
August 9, 2010
- Toho HD to Integrate Asucome on Oct. 1
August 9, 2010
- Daiichi Sankyo's TRIBENZOR (Olmesartan + Amlodipine + HCTZ) Approved in the US
August 9, 2010
- IMS Japan Launches “NPA Family”
August 9, 2010
- NDA for Rufinamide Oral Suspension Accepted by FDA: Eisai
August 9, 2010
- JPMA to Dispatch Investigation Tour Group to US, Europe
August 9, 2010
- Ono Accelerates Development in Oncology Field
August 9, 2010
- Promote Industry-Academia Alliances to Develop Advanced Bioimaging Technology: Dr Yonekura
August 9, 2010
- M3 Sues Mebix's Former Management Team for Inappropriate Accounting
August 9, 2010
- Market for Antidepressants in Japan Part I
August 9, 2010
- Information on Drug Safety Must Be Repeatedly Provided: Ms Furukawa of IMS Japan
August 9, 2010
- Kyowa Pharm., Taiyo Recall Their Theophylline Products
August 9, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…